Prostate Cancer

Biden's 'last known' prostate cancer screening was in 2014, says his office

Former president Joe Biden's last known prostate cancer screening was in 2014, and he had never been diagnosed with the disease before last week, his office said Tuesday. Biden's aides released the new details about his diagnosis amid intense scrutiny of Biden's health during his presidency and skepticism that the disease could have progressed to an advanced stage without being detected. Although Biden's cancer can possibly be controlled with treatment, it has spread to his bones and is no longer curable. The brief statement from Biden's office did not disclose the results of his 2014 PSA blood test. PSA stands for prostate-specific antigen. President Biden's last known PSA was in 2014. Prior to Friday, President Biden had never been diagnosed with prostate cancer, the statement said in its entirety. Biden's cancer was announced on Sunday, prompting a wave of sympathy but also suggestions from some of his critics, including his successor Donald Trump, that the former president and

Reagan, Carter and Biden: A history of US presidents diagnosed with cancer

As Joe Biden begins treatment for prostate cancer, here's a look at other US presidents who faced cancer diagnoses and how their cases were managed

Trump questions Joe Biden's cancer diagnosis timing, hints at cover-up

Donald Trump said Joe Biden's aggressive cancer should have been detected earlier and hinted that information was withheld from the public

Joe Biden's prostate cancer: Risks, symptoms, treatment options explained

Joe Biden's metastatic or stage 4 prostate cancer diagnosis highlights common symptoms, risk factors, and treatment options men should know about

Biden diagnosed with aggressive prostate cancer, reviewing treatment

Former US President Joe Biden's cancer diagnosis appears to be hormone-sensitive, which allows for effective management, a statement from his office read

AstraZeneca India surrenders marketing approval of prostate cancer drug

AstraZeneca Pharma India Ltd on Tuesday said it has surrendered the marketing authorisation of prostate cancer treatment drug Olaparib (Lynparza) 100mg and 150mg in India citing commercial reasons. The company had received marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) on November 17, 2023, AstraZeneca Pharma India said in a regulatory filing. It has now surrendered the marketing authorisation of the indication of Olaparib (Lynparza) 100mg and 150mg, the filing added. "...since the date of receipt of marketing authorisation for the said indications i.e. November 17, 2023, till date, we have never marketed the said indication in India," the company said, adding, "the discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons." The drug is indicated in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate ..

AI shows prostate cancer is not just singular disease, reveals study

Scientists have used artificial intelligence (AI) to reveal a new form of aggressive prostate cancer which they said could help thousands of lives by revolutionising how the disease is diagnosed and treated in the future. The study, published in the journal Cell Genomics, reveals that prostate cancer, which affects one in eight men in their lifetime, includes two different subtypes termed evotypes. The findings, led by researchers at the University of Oxford, and the University of Manchester, UK, could help provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI, they said. Our research demonstrates that prostate tumours evolve along multiple pathways, leading to two distinct disease types," said lead researcher Dan Woodcock, from the University of Oxford. This understanding is pivotal as it allows us to classify tumours based on how the cancer evolves rather than solely on individual gene mutations or expression ...

US Defence Secy Austin hospitalised again, transfers powers to deputy

US Defense Secretary Lloyd Austin, who was diagnosed with prostate cancer in December, was hospitalised again on Sunday following symptoms pointing to an "emergent bladder issue", the Pentagon said. In a statement, the Pentagon said Austin was transported by his security detail to Walter Reed National Military Medical Center around 2.20 pm. While Austin initially was set to retain the "functions and duties of his office", at about 5 pm on Sunday he transferred those authorities to Deputy Secretary of Defense Kathleen Hicks. As of Sunday evening, he remained hospitalised, said Pentagon Press Secretary Maj Gen Pat Ryder. The chairman of the Joint Chiefs of Staff was also notified, as well as the White House and Congress. Ryder said Austin had travelled to the hospital with the unclassified and classified communications systems needed to perform his job. Austin was scheduled to depart on Tuesday for Brussels to hold a meeting of the Ukraine contact group, which he established in 2022

BDR Pharmaceuticals launches prostate cancer drug in oral solution form

BDR stated since BDENZA is in liquid form, they can't quantify how lower it is compared to its counterparts in the market as they are present in solid form (tablet/capsule)

Proton therapy for prostate cancer: does the evidence support the hype?

While there is strong evidence for the benefits of proton therapy in children, it is much less clear in prostate and other adult cancers.

Hormone treatment for prostate cancer tied to heart risks

Results can be particularly important for prostate patients who have risk factors for heart disease